Get started
Spero Therapeutics, Inc.Spero Therapeutics, Inc.Spero Therapeutics, Inc.

Spero Therapeutics, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

SPRO chart


Full chart

SPRO upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪50.31 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
11.6222
Basic EPS (TTM)
0.0814 USD
Net income (FY)
‪22.81 M‬ USD
Revenue (FY)
‪96.73 M‬ USD
Shares float
‪39.50 M‬
Beta (1Y)
1.53

Employees


Employees (FY)
46
Change (1Y)
+11 +31.43%
Revenue / Employee (1Y)
‪2.10 M‬ USD
Net income / Employee (1Y)
‪495.78 K‬ USD

About Spero Therapeutics, Inc.


Sector
Health Technology
Industry
Biotechnology
CEO
Satyavrat Shukla
Website
sperotherapeutics.com
Headquarters
Cambridge
Founded
2013
FIGI
BBG00HXSJ1R2
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on identifying, developing, and commercializing treatments involving bacterial infections, including multi-drug resistant bacterial infections, and rare diseases Its pipeline product candidates include Tebipenem HBr, SPR720, and SPR206. The company was founded by Ankit A. Mahadevia and Laurence Rahme in April 2013 and is headquartered in Cambridge, MA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

SPRO news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of SPRO is 0.9375 USD — it has increased by 1.59% in the past 24 hours. Watch Spero Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Spero Therapeutics, Inc. stocks are traded under the ticker SPRO.
SPRO stock has fallen by −10.71% compared to the previous week, the month change is a −21.22% fall, over the last year Spero Therapeutics, Inc. has showed a −31.07% decrease.
We've gathered analysts' opinions on Spero Therapeutics, Inc. future price: according to them, SPRO price has a max estimate of 5.00 USD and a min estimate of 5.00 USD. Watch SPRO chart and read a more detailed Spero Therapeutics, Inc. stock forecast: see what analysts think of Spero Therapeutics, Inc. and suggest that you do with its stocks.
SPRO reached its all-time high on Dec 28, 2020 with the price of 23.6390 USD, and its all-time low was 0.6801 USD and was reached on Aug 2, 2022. View more price dynamics on SPRO chart.
See other stocks reaching their highest and lowest prices.
SPRO stock is 2.98% volatile and has beta coefficient of 1.53. Track Spero Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Spero Therapeutics, Inc. there?
Today Spero Therapeutics, Inc. has the market capitalization of ‪50.31 M‬, it has decreased by −10.00% over the last week.
Yes, you can track Spero Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Spero Therapeutics, Inc. is going to release the next earnings report on Mar 13, 2025. Keep track of upcoming events with our Earnings Calendar.
SPRO earnings for the last quarter are −0.32 USD per share, whereas the estimation was −0.27 USD resulting in a −20.75% surprise. The estimated earnings for the next quarter are −0.41 USD per share. See more details about Spero Therapeutics, Inc. earnings.
Spero Therapeutics, Inc. revenue for the last quarter amounts to ‪13.47 M‬ USD, despite the estimated figure of ‪23.00 M‬ USD. In the next quarter, revenue is expected to reach ‪6.20 M‬ USD.
SPRO net income for the last quarter is ‪−17.15 M‬ USD, while the quarter before that showed ‪−17.86 M‬ USD of net income which accounts for 4.00% change. Track more Spero Therapeutics, Inc. financial stats to get the full picture.
No, SPRO doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 25, 2024, the company has 46.00 employees. See our rating of the largest employees — is Spero Therapeutics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Spero Therapeutics, Inc. EBITDA is ‪−17.65 M‬ USD, and current EBITDA margin is 20.79%. See more stats in Spero Therapeutics, Inc. financial statements.
Like other stocks, SPRO shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Spero Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Spero Therapeutics, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Spero Therapeutics, Inc. stock shows the sell signal. See more of Spero Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.